Patient Perspectives of Barriers and Facilitators for the Uptake of Pharmacogenomic Testing in Veterans Affairs’ Pharmacogenomic Testing for the Veterans (PHASER) Program
Year: 2023
Type: article
Abstract: We applied implementation science frameworks to identify barriers and facilitators to veterans’ acceptance of pharmacogenomic testing (PGx), which was made available as a part of clinical care at 25 VA medical centers. We conducted 30 min interviews with veterans who accepted (n = 14), declined (n = 9), or were contemplating (n = 8) PGx testing. Six team members coded one transcript from each participant group to develop the codebook and finalize definitions. Three team members coded the remaining 28 transcripts and met regularly with the larger team to reach a consensus. The coders generated a matrix of implementation constructs by testing status to identify the similarities and differences between accepters, decliners, and contemplators. All groups understood the PGx testing procedures and possible benefits. In the decision-making, accepters prioritized the potential health benefits of PGx testing, such as reducing side effects or the number of medications. In contrast, decliners prioritized the possibilities of data breach or the negative impact on healthcare insurance or Veterans Affairs benefits. Contemplators desired to speak to a provider to learn more before making a decision. Efforts to improve the clarity of data security and the impact on benefits may improve veterans’ abilities to make more informed decisions about whether to undergo PGx testing.
Source: Journal of Personalized Medicine
DOI: 10.3390/jpm13091367
Institutions: University of Wisconsin–Madison, Duke University, Durham VA Health Care System, Durham VA Medical Center, United States Department of Veterans Affairs, Veterans Health Administration, Duke Medical Center, Loyola University Chicago, Edward Hines, Jr. VA Hospital, University of North Carolina at Chapel Hill, William S. Middleton Memorial Veterans Hospital
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,224
OpenAlex ID: W4386602341
